Rajender Reddy.

All of the patients provided written informed consent. Study Design In this multicenter, randomized, open-label trial, all the sufferers received a fixed-dosage combination tablet containing 90 mg of ledipasvir and 400 mg of sofosbuvir, administered orally once daily. Randomization was stratified regarding to HCV genotype . Study Assessments The primary efficacy end point was an HCV RNA level of less than 25 IU per milliliter at 12 weeks following the end of therapy . This end point was assessed in every the individuals who underwent randomization and received at least one dosage of a report drug.Tulsa, Okla. Top 10 10 Claims with Flu Activity* Oklahoma Arkansas Mississippi Texas Tennessee Louisiana Alabama Kentucky Nebraska South Carolina *Aggregate data from November 2014 through February 2015 As well as the top markets, the season-ending Index showed the bottom 10, suggesting successful prevention attempts in preparation for, and during flu time of year in these grouped communities, which experienced the cheapest degrees of influenza. Markets with Least Flu Activity* Portland, Ore. Hartford-New Haven, Conn. Boston, Mass. Fresno-Visalia, Calif. Sacramento, Calif. Tucson, Ariz. Buffalo, N.Y. Providence, R.We. Seattle-Tacoma, Wash. Los Angeles *Aggregate data from November 2014 through February 2015 Methodology The Walgreens Flu Index is usually compiled using retail prescription data for antiviral medications used to treat influenza across Walgreens places nationwide.